- Report
- November 2021
- 284 Pages
Global
From €2850EUR$3,000USD£2,452GBP
- Report
- November 2021
- 844 Pages
Global
From €4750EUR$5,000USD£4,086GBP
- Report
- April 2023
- 147 Pages
Global
From €5699EUR$5,999USD£4,903GBP
- Book
- August 2019
- 416 Pages
Phosphodiesterase (PDE) is a class of enzymes that catalyze the hydrolysis of phosphodiester bonds. They are involved in a variety of physiological processes, including signal transduction, metabolism, and cell division. In the pharmaceutical industry, PDE inhibitors are used to treat a variety of conditions, including erectile dysfunction, pulmonary hypertension, and asthma. PDE inhibitors work by blocking the action of the enzyme, allowing for increased levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This can lead to increased blood flow, relaxation of smooth muscle, and improved airway function.
Some companies in the PDE market include Pfizer, GlaxoSmithKline, Merck, and Novartis. Show Less Read more